

# Verena Schroeder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/721695/publications.pdf>

Version: 2024-02-01

48  
papers

1,514  
citations

279798

23  
h-index

315739

38  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1561  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Registry on Factor XIII Deficiency: A basis formed mostly on European data. <i>Thrombosis and Haemostasis</i> , 2007, 97, 914-921.	3.4	129
2	TAFI and PAI-1 levels in human sepsis. <i>Thrombosis Research</i> , 2006, 118, 205-212.	1.7	127
3	Effects of MASP-1 of the Complement System on Activation of Coagulation Factors and Plasma Clot Formation. <i>PLoS ONE</i> , 2012, 7, e35690.	2.5	99
4	Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. <i>Molecular Immunology</i> , 2014, 61, 69-78.	2.2	86
5	Factor XIII: Structure and Function. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 422-428.	2.7	81
6	Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 216-225.	2.0	79
7	Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography. <i>Thrombosis and Haemostasis</i> , 2002, 88, 1020-1025.	3.4	66
8	Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. <i>Thrombosis and Haemostasis</i> , 2003, 90, 434-438.	3.4	65
9	Factor XIII Deficiency: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 632-641.	2.7	62
10	Acquired factor XIII deficiency: a therapeutic challenge. <i>Thrombosis and Haemostasis</i> , 2013, 109, 479-487.	3.4	53
11	MASP-1 of the complement system promotes clotting via prothrombin activation. <i>Molecular Immunology</i> , 2015, 65, 398-405.	2.2	53
12	Influence of Blood Coagulation Factor XIII and FXIII Val34Leu on Plasma Clot Formation Measured by Thrombelastography. <i>Thrombosis Research</i> , 2001, 104, 467-474.	1.7	46
13	Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. <i>Haematologica</i> , 2010, 95, 956-962.	3.5	44
14	Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. <i>Diabetologia</i> , 2014, 57, 1737-1741.	6.3	43
15	Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. <i>Thrombosis and Haemostasis</i> , 2006, 95, 77-84.	3.4	38
16	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 332.	7.4	37
17	International registry on factor XIII deficiency: a basis formed mostly on European data. <i>Thrombosis and Haemostasis</i> , 2007, 97, 914-21.	3.4	33
18	Role of complement in diabetes. <i>Molecular Immunology</i> , 2019, 114, 270-277.	2.2	31

#	ARTICLE	IF	CITATIONS
19	MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model. PLoS ONE, 2018, 13, e0191292.	2.5	31
20	MASP-1 Induced Clotting – The First Model of Prothrombin Activation by MASP-1. PLoS ONE, 2015, 10, e0144633.	2.5	27
21	Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thrombosis and Haemostasis, 2007, 97, 890-898.	3.4	26
22	Factor XIII in severe sepsis and septic shock. Thrombosis Research, 2007, 119, 311-318.	1.7	25
23	Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood, 2010, 115, 5089-5096.	1.4	23
24	Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thrombosis and Haemostasis, 2002, 88, 1020-5.	3.4	19
25	TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assays. Thrombosis and Haemostasis, 2006, 96, 236-237.	3.4	18
26	Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels. Neurology, 2020, 95, e898-e909.	1.1	18
27	Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation. British Journal of Haematology, 2013, 160, 116-119.	2.5	17
28	Relation of depression to various markers of coagulation and fibrinolysis in patients with and without coronary artery disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 782-787.	2.8	15
29	Coagulation factor XIII activation peptide and subunit levels in patients with acute ischaemic stroke: A pilot study. Thrombosis Research, 2010, 126, e122-e127.	1.7	13
30	MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Molecular Immunology, 2019, 114, 1-9.	2.2	12
31	Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. Thrombosis Research, 2017, 159, 96-99.	1.7	11
32	Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. Thrombosis and Haemostasis, 2006, 95, 77-84.	3.4	11
33	Thrombelastographic studies on factor XIII. Thrombosis and Haemostasis, 2010, 104, 1277-1279.	3.4	9
34	Diabetes affects endothelial cell function and alters fibrin clot formation in a microvascular flow model: A pilot study. Diabetes and Vascular Disease Research, 2020, 17, 147916412090304.	2.0	9
35	Nicorandil – Review of Pharmacological Properties and Clinical Applications. Cardiology, 2005, 5, 220-229.	0.3	7
36	Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thrombosis and Haemostasis, 2007, 97, 890-8.	3.4	7

#	ARTICLE	IF	CITATIONS
37	Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. International Journal of Molecular Sciences, 2019, 20, 5963.	4.1	6
38	Free factor XIII activation peptide affects factor XIII function. British Journal of Haematology, 2015, 168, 757-759.	2.5	5
39	Identification of amino acid residues that are crucial for FXIII-A intersubunit interactions and stability. Blood, 2020, 135, 145-152.	1.4	5
40	Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 1496-1506.	3.8	5
41	Role of proteomic technologies in understanding risk of arterial thrombosis. Expert Review of Proteomics, 2009, 6, 539-550.	3.0	4
42	Proline 36 of the Factor XIII Activation Peptide Plays a Crucial Role in Substrate Recognition and Zymogen Activation. Thrombosis and Haemostasis, 2018, 118, 2037-2045.	3.4	4
43	Laboratory Assessment of Coagulation Factor XIII. Hamostaseologie, 2020, 40, 467-471.	1.9	4
44	Identification of a novel nonsense mutation leading to congenital factor XIII deficiency. Thrombosis Research, 2018, 165, 83-85.	1.7	3
45	Coagulation Factor XIII in Cerebral Venous Thrombosis. TH Open, 2019, 03, e227-e229.	1.4	3
46	Illustrated State of the Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
47	An international collaborative study to assign value for Total Factor XIII Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. Journal of Thrombosis and Haemostasis, 2022, 20, 525-531.	3.8	2
48	Factor XIII activation by thrombin depends on FXIIIVal34Leu genotype. Blood, 2003, 101, 371-371.	1.4	1